In this subset of tumours, over the last 10 years, significant improvements in progression free survival (PFS) has been achieved through the definition of a tailored treatment against the so-called “EGFR-sensitizing mutations” and the development of first-, second-, and third-generation tyrosine kinases inhibitors (TKIs) [6,7,8,9,10,11,12,13]. The gene discussed is EGFR; the disease is neoplasm.